Chengdu Kanghua Biological Products Co Ltd Class A 300841
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 61.46
- Day Range
- CNY 59.85–62.00
- 52-Week Range
- CNY 44.78–84.31
- Bid/Ask
- CNY 60.09 / CNY 60.11
- Market Cap
- CNY 8.09 Bil
- Volume/Avg
- 1.4 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 13.51
- Price/Sales
- 4.99
- Dividend Yield (Trailing)
- 3.25%
- Dividend Yield (Forward)
- 3.25%
- Total Yield
- 3.33%
Company Profile
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 672
- Website
- https://www.kangh.com
Comparables
Valuation
|
Metric
|
300841
|
688670
|
300142
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.51 | 22.30 | 43.32 |
Price/Book Value | 2.25 | 1.52 | 2.44 |
Price/Sales | 4.99 | 51.93 | 5.86 |
Price/Cash Flow | 12.25 | 70.79 | 26.57 |
Price/Earnings
300841
688670
300142
Financial Strength
|
Metric
|
300841
|
688670
|
300142
|
|---|---|---|---|
Quick Ratio | 4.14 | 1.40 | 2.46 |
Current Ratio | 4.49 | 3.34 | 2.85 |
Interest Coverage | 119.95 | −80.32 | 47.19 |
Quick Ratio
300841
688670
300142
Profitability
|
Metric
|
300841
|
688670
|
300142
|
|---|---|---|---|
Return on Assets (Normalized) | — | −4.87% | 3.37% |
Return on Equity (Normalized) | — | −5.91% | 5.57% |
Return on Invested Capital (Normalized) | — | −5.65% | 3.91% |
Return on Assets
300841
688670
300142
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nmxbfjyyl | Ptbk | $598.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pscgpchs | Dsnplg | $115.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bmbhdpdc | Vbxxcrv | $109.5 Bil | |
MRNA
| Moderna Inc | Mfjfywx | Gjfn | $54.0 Bil | |
BNTX
| BioNTech SE ADR | Bxvnjfywg | Zvrp | $24.7 Bil | |
ARGX
| argenx SE ADR | Xflnzrwh | Lxblt | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qzlmbglg | Mwjlvbb | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vfzjbkjd | Przcbp | $14.5 Bil | |
INCY
| Incyte Corp | Rsjwmvjb | Rbdyrcy | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sdpxzgrm | Mpndhmt | $12.3 Bil |